Numbers needed to treat derived from meta-analyses - sometimes informative, usually misleading

被引:204
作者
Smeeth, L
Haines, A
Ebrahim, S [1 ]
机构
[1] Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England
[2] UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 1999年 / 318卷 / 7197期
关键词
D O I
10.1136/bmj.318.7197.1548
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Numbers needed to treat are often used to summarise treatment effects in a clinically relevant way. They are derived from the baseline risk without treatment and the reduction in risk achieved with treatment. Numbers needed to treat are sensitive to factors that change the baseline risk such as the outcome considered, patients' characteristics, secular trends in incidence and case fatality, and the clinical setting. Pooled numbers needed to treat derived from meta-analyses can be seriously misleading because the baseline risk often varies appreciably between the trials. Applying the pooled relative risk reductions calculated from meta-analyses or individual trials to the baseline risk relevant to specific patient group produces a useful number needed to treat.
引用
收藏
页码:1548 / 1551
页数:4
相关论文
共 33 条
[1]   Confidence intervals for the number needed to treat [J].
Altman, DG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7168) :1309-1312
[2]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[3]  
*COCHR COLL, 1998, COCHR LIB
[4]   THE NUMBER NEEDED TO TREAT - A CLINICALLY USEFUL MEASURE OF TREATMENT EFFECT [J].
COOK, RJ ;
SACKETT, DL .
BRITISH MEDICAL JOURNAL, 1995, 310 (6977) :452-454
[5]  
Cranney M, 1996, BRIT J GEN PRACT, V46, P661
[6]   Reductase inhibitor monotherapy and stroke prevention [J].
Crouse, JR ;
Byington, RP ;
Hoen, HM ;
Furberg, CD .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (12) :1305-1310
[7]  
CUCHERAT M, 1997, EASYMA 1997 METAANAL
[8]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[9]  
EBRAHIM S, 1996, HLTH PROMOTION OLDER
[10]   Meta-analysis: Principles and procedures [J].
Egger, M ;
Smith, GD ;
Phillips, AN .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7121) :1533-1537